Diabetes drugs, which also help fight excess weight, have become a real hit and brought manufacturers into the top 5 companies in terms of profit. Novo Nordisk and Eli Lilly are experiencing a real boom: their drugs Vegovi and Ozempic are not only popular, but also become the object of speculation on the stock exchanges.
The demand for these drugs is explained by the problem of obesity, which affects more than 42% of American adults. New drugs based on the semaglutide molecule offer the opportunity to lose weight without significant changes in lifestyle, which is especially appreciated in the USA and Europe.
However, behind all the ease and comfort of using these drugs, there are serious side effects. From gastrointestinal issues to the potential risk of thyroid cancer, the use of these medications requires careful consideration. Despite the possible health risks, the popularity of these drugs is rapidly growing, and new Russian analogues such as Semavik are already preparing to enter the market.
Experts advise caution when using these medications and view them as a tool in an overall obesity treatment plan rather than a quick fix for weight loss. Instead of surrendering to trends, it is better to opt for traditional methods, taking into account all possible risks and side effects.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
